In a monumental leap for synthetic genomics, researchers have unveiled an innovative method that surmounts the formidable challenge of delivering megabase-scale synthetic DNA from microorganisms into mammalian cells. This technique, termed nucleus isolation for chromosome extraction (NICE), introduces a groundbreaking platform that bridges the vast evolutionary divide, enabling the transplantation of synthetic megabase-length DNA constructions directly into mammalian embryos with unparalleled precision and efficiency. The development holds transformative potential, promising to redefine our ability to manipulate and study large-scale genetic constructs within complex biological systems.
Transferring large synthetic DNA molecules across species has historically been impeded by the fragility of the DNA constructs and the host immune and cellular machinery’s constraints. Conventional approaches often fail to maintain the structural and epigenetic integrity of these synthetic genomes during delivery. The NICE method innovatively addresses this by isolating intact yeast nuclei containing synthetic DNA while preserving their native chromatin architecture. Harnessing the unique epigenomic landscape of Saccharomyces cerevisiae—a model organism notably devoid of cytosine methylation and repressive histone modifications—researchers encapsulated synthetic DNA within these nuclei, creating a natural protective vehicle for transfer.
The core of this pioneering protocol lies in isolating nuclei from genetically engineered yeast cells in a manner that maintains megabase-size synthetic chromosomes intact and transcriptionally naive. This isolation preserves the chromatin’s native state, avoiding the epigenetic reprogramming that can occur outside its natural nuclear context. Subsequent to isolation, these nuclei are introduced into mouse early embryos, which are in a developmental phase characterized by a naive epigenetic state, conducive to the establishment of de novo chromatin modifications and gene regulatory programs. This stage-specific receptivity opens avenues for real-time observation of epigenetic remodeling events following introduction of foreign synthetic DNA.
Crucially, NICE enables near-perfect delivery efficiency through microinjection techniques that transfer isolated yeast nuclei directly into embryos. This reliable methodology stands in stark contrast to traditional gene transfer mechanisms, often fraught with inefficiencies, fragmented DNA integration, or loss of epigenetic information. The protocol reports reaching 100% successful delivery rates of intact synthetic chromosomal DNA into the nuclear environment of mouse zygotes, paving the way for robust exploration of synthetic genomics within mammalian developmental systems.
Complementing the physical transfer process, the methodology incorporates rigorous quality control steps, including pulsed-field gel electrophoresis, to verify the integrity and size of the isolated DNA molecules. This ensures that synthetic chromosomes subjected to the protocol retain their structural fidelity throughout the isolation and transfer stages. Importantly, the isolated nuclei maintain a high concentration and purity level, allowing for long-term storage at ultra-low temperatures (-80 °C) for periods exceeding six months without compromising their viability or the synthetic DNA’s structural integrity.
This innovative fusion of yeast biology with mammalian embryo technology exploits the former’s distinct chromatin characteristics, effectively circumventing common barriers in cross-species genomic manipulation. Saccharomyces cerevisiae, lacking complex DNA methylation systems and certain repressive histone marks typical in higher eukaryotes, provides a simplified genomic environment where synthetic DNA chromosomes can be constructed and maintained with fewer epigenetic modifications. The encapsulation of such DNA within yeast nuclei thus facilitates its safe transport and gradual epigenetic adaptation once inside the mammalian embryo.
The implications of this work are far-reaching. By establishing a controlled system to study the onset and development of epigenetic modifications upon integration of synthetic DNA, scientists can dissect the influence of chromatin states on transcriptional activation in unprecedented detail. This knowledge is vital to understanding complex gene regulatory networks, potentially revolutionizing developmental biology, synthetic biology, and regenerative medicine.
Intriguingly, the protocol’s adaptability makes it compatible with various synthetic DNA constructs, opening avenues beyond yeast chromosomes to include human synthetic genomes or other large DNA assemblies. This versatility signals a new era where entire synthetic chromosomes—encoding complex traits, metabolic pathways, or therapeutic genes—can be efficiently translocated into mammalian systems for functional assays or clinical applications.
Notably, the successful integration and preservation of synthetic DNA in a naive embryonic environment provide a unique opportunity to follow chromatin remodeling and gene expression dynamics from the earliest stages of mammalian development. This allows researchers to map how foreign genetic material becomes epigenetically assimilated, which genes are activated or silenced, and how these patterns influence organismal phenotypes over time.
The high degree of control and specificity afforded by NICE elevates it as a prime tool for genome engineering initiatives that require megabase-scale modifications, such as synthetic chromosome construction, large gene cluster transplantation, or the introduction of novel functional elements. The method’s scalability and robustness ensure it can be integrated into existing workflows in genetic engineering laboratories with proficiency in mammalian embryo microinjection.
While the protocol demands familiarity with mammalian microinjection techniques, its temporal efficiency is noteworthy. The entire process—from yeast nuclei isolation and quality verification to delivery into mammalian embryos—is completed within approximately five days. This rapid turnaround accelerates experimental cycles and expedites the iterative process of synthetic genome design, delivery, and functional evaluation.
The ability to store isolated yeast nuclei at -80 °C for extended periods also enhances experimental flexibility and planning, allowing researchers to generate batches of nuclei in advance and use them as needed without repeated preparation. This storage capability is a critical practical advancement for labs aiming to conduct large-scale or longitudinal studies involving synthetic genomic elements.
This method sets a precedent for future work in synthetic genomics, exemplifying how cross-kingdom genetic material transfer can be finely controlled to preserve intricate epigenomic configurations and facilitate downstream biological inquiries. Researchers anticipate that NICE will invigorate efforts to create synthetic mammalian genomes, model complex diseases, or engineer organisms with enhanced functionalities.
In summary, NICE represents a tour de force in genome engineering by seamlessly integrating yeast synthetic chromosomes into mammalian embryonic systems with unmatched accuracy, purity, and viability. It transcends prior limitations of DNA delivery technologies, enabling comprehensive studies of de novo epigenetic regulation and gene expression patterns emanating from synthetic DNA. This transformative approach unlocks new vistas for understanding genetic regulation and advancing synthetic biology with profound implications for medicine and biotechnology.
Subject of Research: Delivery of synthetic megabase-scale DNA into mammalian embryos using isolated yeast nuclei.
Article Title: Yeast nuclei–mediated precise delivery of synthetic megabase-scale human DNA into mammalian embryos.
Article References:
Liu, Y., Zhou, J., Liu, Z. et al. Yeast nuclei–mediated precise delivery of synthetic megabase-scale human DNA into mammalian embryos. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01374-6
Image Credits: AI Generated
